![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharmanet Development Grp (MM) | NASDAQ:PDGI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.04 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 12, 2008
______________
PharmaNet Development Group, Inc.
( Exact Name of Registrant as Specified in Charter)
_____________
|
|
|
Delaware |
001-16119 |
59-2407464 |
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
504 Carnegie Center, Princeton, NJ 08540
(Address of Principal Executive Offices) (Zip Code)
(609) 951-6800
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 12, 2008, the Compensation Committee of PharmaNet Development Group, Inc. (PDGI or the Company), approved a three year extension to the terms of the employment agreement of its President and Chief Executive Officer, Jeffrey P. McMullen. Accordingly, Mr. McMullens employment agreement will now expire on December 31, 2011.
The additional material terms of Mr. McMullens existing employment agreement remained unchanged, except to the extent necessary to comply with Section 409A of the Internal Revenue Code.
The employment agreement will be filed as an exhibit to PDGIs annual report on Form 10-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
December 17, 2008
PHARMANET DEVELOPMENT GROUP, INC. |
||
|
By: |
/s/ John P. Hamill |
|
|
Name: John P. Hamill |
|
|
Title: EVP and Chief Financial Officer |
1 Year Pharmanet Development Grp (MM) Chart |
1 Month Pharmanet Development Grp (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions